Eroxon® Granted Marketing Authorisation in Mexico

Eroxon® Granted

Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces that the Mexican Secretariat of Health has granted over the counter sale ("OTC") Marketing Authorisation for Eroxon®, the Company's breakthrough, topical gel formulation for the treatment of erectile dysfunction ("ED").

Eroxon® can now be marketed in Mexico as a topical treatment for ED available OTC without the need for a prescription. Eroxon® is approved as an effective, clinically proven treatment for ED with a 10-minute onset of action.

The prevalence of ED disrupts the lives of at least 1 in 5 men globally1. Mexico currently has a population of 129 million².

MED3000 has already been approved as the first pan-European clinically proven topical treatment for ED available OTC and is now available in a growing number of EU and Middle East markets. Initial launches commenced under the brand name Eroxon® in March 2023, with commercial agreements in key markets including the European Economic Area, UK, Switzerland, South Korea, Latin America and the Middle East.

James Barder, Chief Executive Officer of Futura said: "Following the approval by the US FDA earlier this year, Mexican marketing authorisation opens up another very large and exciting market for Eroxon®. Mexico is a vibrant and dynamic market, and we look forward to bringing the benefits of Eroxon® to ED sufferers in Mexico with our commercial partner M8."

EMA, Withdrawal assessment report for Viagra, 2008

• EMA, Withdrawal assessment report for Viagra, 2008
• https://www.unfpa.org/data/world-population/MX